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Introduction: Micronized dehydrated human amnion/chorion membrane (μ-dHACM) is derived from donated
human placentae and has anti-inflammatory, low immunogenic and anti-fibrotic properties. The objective of this
study was to quantitatively assess the efficacy of μ-dHACM as a disease modifying intervention in a rat model of
osteoarthritis (OA). It was hypothesized that intra-articular injection of μ-dHACM would attenuate OA progression.
Methods: Lewis rats underwent medial meniscal transection (MMT) surgery to induce OA. Twenty four hours
post-surgery, μ-dHACM or saline was injected intra-articularly into the rat joint. Naïve rats also received μ-dHACM
injections. Microstructural changes in the tibial articular cartilage were assessed using equilibrium partitioning of an
ionic contrast agent (EPIC-μCT) at 21 days post-surgery. The joint was also evaluated histologically and synovial fluid
was analyzed for inflammatory markers at 3 and 21 days post-surgery.
Results: There was no measured baseline effect of μ-dHACM on cartilage in naïve animals. Histological staining of
treated joints showed presence of μ-dHACM in the synovium along with local hypercellularity at 3 and 21 days
post-surgery. In MMT animals, development of cartilage lesions at 21 days was prevented and number of partial
erosions was significantly reduced by treatment with μ-dHACM. EPIC-μCT analysis quantitatively showed that
μ-dHACM reduced proteoglycan loss in MMT animals.
Conclusions: μ-dHACM is rapidly sequestered in the synovial membrane following intra-articular injection and
attenuates cartilage degradation in a rat OA model. These data suggest that intra-articular delivery of μ-dHACM
may have a therapeutic effect on OA development.Introduction
Osteoarthritis (OA) is a degenerative joint disease that is
currently the leading cause of chronic disability in the US
[1]. Additionally, it is the single most expensive condition
among Medicare patients in the US [2]. OA is character-
ized by chronic degeneration of the articular cartilage
through processes such as depletion of proteoglycans
(PG), hypertrophic differentiation of chondrocytes, surface
erosion, lesion formation and mineralization of the* Correspondence: robert.guldberg@me.gatech.edu
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reproduction in any medium, provided the orextracellular matrix (ECM) [3,4]. Current treatment op-
tions are targeted towards symptomatic management via
pain relief drugs or surgical intervention; however, both
have clear limitations [4]. Non-steroidal anti-inflammatory
drugs (NSAIDs) are the most commonly used class of pain
relief drugs but have strong side-effect profiles including
gastro-intestinal complications [1]. Grafting and surgical
reconstructions on the other hand are associated with
poor outcomes and associated pain [4]. Clinical trials have
tested a number of potential disease modifying OA drugs
(DMOADs), including matrix-metalloproteinase inhibitors
(MMPis), cytokine blockers, inhibitors of inducible nitric
oxide synthase (iNOS), and doxycycline; however, none
have shown a clear therapeutic benefit to date [5]. There
are multiple DMOADs in clinical trials, such as rhFGF-18
(Sprimerfin by Merck), a growth factor based therapy, inLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and volume in patients with OA [6]. Strontium ranelate,
in a recently completed Phase 3 clinical trial showed a
significant improvement in the joint structure of OA
patients [7]. Although heavy investment in research
continues, OA remains a pervasive and burdensome
condition with limited effective clinical options, and
there is still a critical need to investigate novel OA
therapies.
Testing therapeutics for OA requires selection of a
suitable animal model and an efficient and quantitative
analysis method. The medial meniscal transection (MMT)
rat model is a well- accepted small animal model for
evaluating new pharmacologic agents [8]. Although the
MMT model is considered a screening model, the predom-
inant analytical method, histology, is a slow, costly, and
labor intensive process with poor sensitivity due to the two-
dimensional semi-quantitative nature of histopathological
scoring [8,9]. In comparison, micro-computed tomography
(μCT) imaging can more rapidly and quantitatively evaluate
three-dimensional morphologic and degenerative changes
in articular cartilage by adaption with a technique relying
on the equilibrium partitioning of an ionic contrast agent
(EPIC-μCT) [10]. This technique is based on the principle
that compared to healthy cartilage degenerated cartilage
contains a lower proteoglycan content and, therefore, a
higher concentration of a negatively charged contrast
agent at equilibrium. Previous studies have validated this
methodology to quantify compositional and structural
changes, such as cartilage proteoglycan content, thickness
and volume [9,11,12]. Our previous study has character-
ized the rat MMT model using EPIC-μCT and demon-
strated changes in the articular cartilage [13]. These
studies have further demonstrated the sensitivity to detect
chemically- or mechanically-induced degenerative changes.
However, EPIC-μCT has not previously been applied to
the evaluation of the efficacy of potential OA therapeutics.
Locally delivered ECM proteins are a promising treat-
ment strategy being developed for a wide range of regen-
erative applications [14]. Dehydrated human amnion/
chorion membrane (dHACM) is a tissue derived from
donated placentae which possesses anti-inflammatory
properties, displays low immunogenicity and promotes
wound healing while inhibiting scar formation [15-17].
There is an established precedence of using this tissue
for regenerative applications clinically, ranging from cor-
neal defects to tendon repair [18-23].
The potential for dHACM to modulate the development
of OA has not been previously investigated; however, in-
direct evidence suggests that it may have beneficial effects
on cartilage. In vitro, dHACM has been shown to main-
tain chondrocyte phenotype when seeded with chondro-
cytes [24,25]. In vivo, chondrocyte seeded dHACM
enhanced regeneration of hyaline cartilage in rabbitosteochondral defects after eight weeks [26]. One of the
limitations of these previous studies has been the use of
dHACM in the form of sheets which can only treat large
defects and would require an invasive surgery. Micron-
ized dHACM (μ-dHACM) offers a minimally invasive,
injectable therapy with a longer shelf life than cellular-
ized constructs. μ-dHACM can be devitalized while pre-
serving its basement membrane structure and a variety
of growth factors, including platelet-derived growth fac-
tor (PDGF), fibroblast growth factor (FGF) and trans-
forming growth factor-beta (TGF-β) [27].
An injectable formulation of μ-dHACM (EpiFixW In-
jectable, MiMedx Group, Inc. Marietta, GA, USA) has
recently been developed that retains the active factors of
the original tissue and allows for minimally invasive local
delivery targeted to the disease site. μ-dHACM is devel-
oped after the native amnion undergoes the PURIONW
process which maintains bioactive components despite
the tissue being devitalized and dehydrated (US Patent
8,357,403– Placenta Tissue Grafts. US Patent 8,372,437-
Placenta Tissue Grafts.14. US Patent 8,409,626-Placenta
Tissue Grafts). The tissue retains the epithelial and chor-
ion layer after the process. A recent study examined the
biological properties of μ-dHACM and in vitro experi-
ments show quantifiable levels of various growth factors,
interleukins and tissue inhibitors of metalloproteinases
(TIMPS). A subcutaneous in vivo experiment in the
same study demonstrated recruitment of mesenchymal
progenitor cells to the site of implantation as well. The
objective of this study was to quantitatively assess the ef-
ficacy of μ-dHACM as a disease modifying intervention
in the rat MMT model of joint degeneration. It was hy-
pothesized that a single intra-articular injection of μ-




Weight matched adult male Lewis rats (Charles River,
Wilmington, MA, USA) weighing 300 to 325 g, were ac-
climated for one week. For the MMT surgery, the ani-
mals were anesthetized with isoflurane, and the skin
over the medial aspect of the left femoro-tibial joint was
shaved and aseptically prepared. The medial collateral
ligament (MCL) was exposed by blunt dissection and
transected to reflect the meniscus toward the femur.
The joint space was visualized, and a full thickness cut
was made through the meniscus at its narrowest point
[28]. The skin was closed with 4.0 Vicryl sutures and
then stapled using wound clips. Twenty-four hours post
MMT surgery, either μ-dHACM (AmnioFixW Injectable,
MiMedx Group Inc. Marietta, GA, USA) or saline was
injected intra-articularly into the stifle joint of the left leg
(n = 5 per group, per time point). We have previously
Table 1 Summary of experimental groups and outcome
measurements
Groups Day 3 measurements Day 21 measurements
μ-dHACM Histology (full joint) Histology (femora only)
(naïve rats) Synovial fluid analysis Synovial fluid analysis
Control: Saline Micro-CT
(naïve rats)
μ-dHACM + MMT rats Histology (full joint) Histology (femora + tibiae
Control: Saline + Synovial fluid analysis separate)
MMT rats Synovial fluid analysis
Micro-CT
CT, computed tomography; MMT, medial meniscal transection; μ-dHACM,
micronized dehydrated human amnion/chorion membrane.
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showing no effect of the surgery on rat ambulatory move-
ments (Additional file 1: Figure S1). The μ-dHACM was
sourced from two different donors processed in two differ-
ent batches. The μ-dHACM was resuspended according
to the product insert and injected into the articular joint
space using a 25 gauge needle. Naïve animals did not
undergo any surgical procedure and were injected with
μ-dHACM or saline. The μ-dHACM was manufactured
using the proprietary PURIONW process and is compliant
with the American Association of Tissue Banks regula-
tions for donor tissues (MiMedx Group, Inc. Marietta,
GA, USA). This process produces a dehydrated, devita-
lized amnion and chorion tissue graft which is then mi-
cronized, sterilized and can be suspended in saline (US
Patent 8,357,403– Placenta Tissue Grafts; US Patent
8,372,437-Placenta Tissue Grafts; US Patent 8,409,626-
Placenta Tissue Grafts). Animals were euthanized at three
or twenty-one days post-surgery. The Georgia Institute of
Technology Institutional Animal Care and Use Commit-
tee approved the experimental procedures for these
in vivo studies (IACUC protocol #A09007).
Synovial fluid analysis
Rats were euthanized via CO2 inhalation at three days or
twenty-one days post-surgery for both the naïve group
and the MMT surgery group. Synovial fluid was col-
lected by first injecting 100 μl of saline intra-articularly
using a 30 gauge insulin syringe, followed by aspirating
approximately 50 to 100 μl of the synovial fluid and sa-
line using the same syringe. Synovial fluid was analyzed
using the QuantibodyW Rat Inflammation Array 1, a
multiplex ELISA kit that quantitatively measured 10 rat
inflammatory factors: IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-
6, IL-10, IL-13, monocyte chemoattractant protein-1
(MCP-1), and TNFα (RayBiotech, Norcross, GA, USA).
EPIC-μCT analysis of articular cartilage
Articular cartilage structure and composition were quanti-
tatively evaluated in the tibial plateau as described in our
previous study [13]. Scanco evaluation software was used
to assess three-dimensional morphological parameters
and local attenuation. Dissected tibia were immersion
fixed in 10% neutral buffered formalin for 48 hours then
stored in 70% ethanol until ready for scanning. Immedi-
ately prior to scanning, tibiae were immersed in 2 ml of
30% Hexabrix™ 320 contrast agent (Covidien, Hazelwood,
MO, USA) and 70% PBS at 37°C for 30 minutes [9,10].
Samples were then scanned using a μCT 40 (Scanco
Medical, Brüttisellen, Switzerland) at 45 kVp, 177 μA,
200 ms integration time, and a voxel size of 16 μm [9].
Raw data were automatically reconstructed to two-
dimensional grayscale tomograms. These were rotated
to sagittal sections, and the cartilage was contoured andthresholded with global segmentation parameters (Gauss
sigma - 1.2, support - 2, threshold - 175 to 225). Direct
distance transformation algorithms were used to quantify
three-dimensional morphology [9,29,30]. The subsequently
generated three-dimensional images were delineated into
three volumes of interest (VOIs). For the MMT model,
images were evaluated for: 1) full articular cartilage in
the proximal tibia including medial and lateral aspects;
2) medial 1/3 of the medial tibial plateau; and 3) focal
lesions on the medial plateau only. Outcome measures
included average articular cartilage thickness, volume
and attenuation. Cartilage attenuation is a quantitative
parameter that is inversely proportional to sulfated gly-
cosaminoglycan (sGAG) content [10]. Degraded cartil-
age contains lower sGAG content and, therefore, higher
contrast agent content and higher attenuation values
[9]. Two outcome measures were defined for evaluation
of focal defects: erosion (defect depth extending to less
than 50% of cartilage thickness) and lesion (defect depth
extending to more than 50% of cartilage thickness) [31].
To define VOIs of focal lesions, manual contouring was
performed in the isolated lesion area to account for the
curvature of the surrounding cartilage tissue and exclude
the subchondral bone and surrounding air. Within this
VOI, segmented cartilage volume was subtracted from the
total volume evaluated to compute lesion volume. A sum-
mary of the various outcome measures is presented in
Table 1.Histology: synovium and cartilage
For the three day time point, the entire limb was har-
vested with knee joint intact, fixed in 10% neutral buff-
ered formalin for three to four days, transferred to 70%
ethanol and stored at 4°C. For the 21 day time point,
the tibiae and femora were harvested separately, dis-
sected free of surrounding tissues, fixed in 10% neutral
buffer formalin for three to four days, transferred to 70%
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was taken to preserve the synovium, meniscus and
femoro-meniscal connective tissue. Following EPIC-μCT
scanning at 21 days, tibiae and femora were decalcified
in Cal-Ex II (Fisher Scientific, Waltham, MA, USA) for
14 days. Dehydrated samples were routinely processed
into paraffin embedded blocks. For comparison with
EPIC-μCT images, sagittal sections were cut at 5 μm
thickness. Sections were stained for sGAGs with a 0.5%
Safranin-O (Saf-O) solution and a 0.2% aqueous solution
of FastGreen as a counter-stain or with hematoxylin and
eosin (H&E).
Statistical analysis
All quantitative data were expressed as mean ± standard
error. Cartilage morphology and composition parametersFigure 1 Representative histology images of μ-dHACM treated joints
treated naïve joints and saline treated naïve joints. E-H are zoomed in vers
μ-dHACM is visible at three days as fibrillar eosinophilic material, as indicate
areas around dHACM fragments. I) MCP-1 levels in μ-dHACM treated and s
days in both saline and μ-dHACM injected groups compared to twenty-on
μ-dHACM injected joints compared to saline treated joints. **P <0.05 for M
MCP-1 levels at day three in saline injected and μ-dHACM injected joints. n
micronized dehydrated human amnion/chorion membrane.between groups were evaluated using a one factor (left
versus right) analysis of variance (ANOVA) with Tukey’s
test for post-hoc analysis. Cartilage morphology and
composition parameters within the same group were
compared between experimental and control knees using
paired t-tests. Statistical significance was set at P <0.05.
All data were analyzed using GraphPad Prism software
version 5.0 (GraphPad Software, Inc., La Jolla, CA, USA).
Results
μ-dHACM injected into naïve joints
μ-dHACM was injected into naïve joints to assess the
inflammatory response at three and twenty-one days.
Histology three days post-injection showed μ-dHACM
particles incorporated into the adjacent synovial tissue
(Figure 1). The material appeared as variably-sizedand MCP-1 data. A-H) Representative histology images of μ-dHACM
ions of regions of interest (black box) defined in A-D, respectively.
d by the black arrows (E and G). Hypercellularity was observed in
aline injected naïve rats. MCP-1 levels were significantly higher at three
e days. The MCP-1 level at three days was significantly higher in the
CP-1 levels at three and twenty-one days for both groups. *P <0.05 for
= 5. MCP-1, monocte chemoattractant protein-1; μ-dHACM,
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ial. dHACM fragments were surrounded by moderate
inflammatory infiltrate consisting of macrophages, lym-
phocytes and plasma cells indicating an inflammatory
response to the xenogeneic material. No fragments were
observed in control samples injected with saline, and
these samples exhibited minimal hemorrhage or inflam-
matory cell presence in the synovial membrane. At 21
days post-surgery, histological staining of μ-dHACM
treated stifle joints showed the continued presence of
μ-dHACM in the synovium along with inflammatory
cells. At twenty-one days, a distribution of smaller sized
dHACM particles appeared compared to the three-day
time point and a similar foreign body response was ob-
served surrounding the μ-dHACM fragments at both
time points (Figure 1). Synovial fluid showed a signifi-
cant increase in MCP-1 concentration in μ-dHACM-
treated joints compared to control joints at three days
but no difference was observed at twenty-one days.
MCP-1 levels significantly decreased from day three to
day twenty-one in both treated and untreated groups
(Figure 1). The other cytokines tested did not show anyFigure 2 Effect of μ-dHACM on naïve tibial cartilage. A) Representative
saline injected samples in naïve joints. B) Average cartilage attenuation. C)
21 days. No differences in cartilage parameters were observed between μ-d
partitioning of an ionic contrast agent-micro computed tomography; μ-dHsignificant differences or were below the limit of detec-
tion. Numerical values for all cytokines are presented in
Additional file 2: Table S1.
Cartilage structure and composition were assessed at
21 days using EPIC-μCT. Representative three-dimensional
reconstructions of the cartilage with thickness heat maps
appeared normal in structure in naïve animals treated with
μ-dHACM or saline (Figure 2). Quantitative assessments
of cartilage volume and thickness indicated no differences
between saline and μ-dHACM treated joints (Figure 2).
Similarly, cartilage attenuation showed no significant dif-
ference between saline and μ-dHACM treated joints, indi-
cating no differences in PG content (Figure 2). No lesions
or erosions were observed in saline or μ-dHACM injected
naïve joints.
μ-dHACM injected into MMT joints
MMT joints were injected with μ-dHACM or saline, and
the effects on the joint and synovium were assessed at
three and twenty-one days. Histological analysis showed
μ-dHACM incorporated into the synovium at both time
points. As observed in naïve joints, the amnion fragmentsEPIC-μCT tibial articular cartilage thickness maps for μ-dHACM and
Average cartilage thickness. D) Average cartilage volume measure at
HACM and saline injected groups. n = 5. EPIC-μCT, equilibrium
ACM, micronized dehydrated human amnion/chorion membrane.
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appeared reduced in size at 21 days. No fragments were
visible in saline treated MMT animals at either three or
twenty-one days (Figure 3). In the saline treated MMT an-
imals at 21 days, lesions and areas of erosion were evident
along with diminished Saf-O staining of the tibial surface
suggesting loss of PG content. In contrast, histological
analysis of dHACM treated joints showed a smooth car-
tilage surface with no lesions and strong Saf-O staining
(Figure 3) (Additional file 3: Figure S2 shows additional
images). Histological observations did not indicate any
differences in cartilage morphology between the two
groups at three days. Synovial fluid collected at three
and twenty-one days showed no significant differences
and most cytokines were below the limit of detection.
Numerical values for all cytokines are shown in the
Additional file 2: Table S1.
EPIC-μCT was used to characterize cartilage and focal
defects at 21 days (Figure 4). Representative planes and
two-dimensional EPIC-μCT attenuation heat maps of
the tibial section from μ-dHACM treated MMT joints
and saline injected MMT joints are presented (Figure 4).
Qualitatively, MMT animals with saline injections dis-
played noticeable cartilage focal lesions and erosion sites.
In contrast, cartilage surfaces in μ-dHACM treated
joints appeared more consistently uniform, and no le-
sions were observed. Quantitative EPIC-μCT at 21 days
post-surgery showed that μ-dHACM treated joints had
lower cartilage attenuation, indicating higher PG con-
tent, in the medial one-third of the tibial plateauFigure 3 Effect of μ-dHACM on MMT joints as depicted by histology.
treated MMT joints and saline treated MMT joints. μ-dHACM visible at three
(A and C). Hypercellularity observed in the area around dHACM fragments
arrows indicate damaged cartilage surface (H). No damage was observed in
for PGs were observed in saline treated MMT joints (H) at 21 days. MMT, m
dehydrated human amnion/chorion membrane.compared to saline injected MMT joints. There was no
significant difference between average attenuation values
between naïve joints and μ-dHACM-treated MMT
joints, suggesting the treatment maintained PG content
comparable to intact joints (Figure 5). MMT joints
injected with saline had an average incidence of 2.8 ±
0.2 erosion and 2.4 ± 0.4 lesion sites per medial tibial
plateau with an average lesion volume of .00725 ± .005
mm3. μ-dHACM treated MMT joints displayed signifi-
cantly fewer erosion sites (1.2 ± .374) and no lesions
(Figure 5).
Discussion
There is an unmet medical need for OA therapeutics as
no DMOADs have been approved for clinical use. ECMs
such as dHACM are a promising therapeutic strategy
due to their mix of ECM proteins, growth factors and
anti-inflammatory factors [32]. Human dHACM allo-
grafts also have an established precedence in clinical ap-
plications ranging from corneal defects to tendon repair
[18,21]. The objective of this study was to quantitatively
assess the efficacy of μ-dHACM (EpiFixW Injectable) as a
disease modifying intervention in a rat model of OA.
EPIC-μCT image analysis provided three-dimensional,
non-destructive and quantitative evaluation of changes
in articular cartilage composition and morphology. The
EPIC-μCT data showed a significant reduction in cartil-
age damage in the form of higher PG levels (lower aver-
age attenuation), fewer incidences of erosions and no
lesions in the MMT joints treated with μ-dHACM. AsA-D) Representative H & E stained histology images of μ-dHACM
days as fibrillar eosinophilic material as indicated by the black arrows
. E-H) Representative Safranin-O stained histology images of tibia. Black
μ-dHACM treated MMT joints (G) whereas erosions and weak staining
edial meniscal transection; PGs, proteoglycans; μ-dHACM, micronized
Figure 4 EPIC-μCT images depicting therapeutic effect of μ-dHACM in MMT joint. A) Representative image isolating erosion in MMT joint.
B) Attenuation map indicating erosion on the MMT joint (Inset shows zoomed in view of erosion). C) Representative image isolating lesion in
MMT joint. D) Attenuation map indicating erosion on the MMT joint (Inset shows zoomed in view of erosion). E-F) Pseudocolor attenuation map
for EPIC-μCT sagittal tibial section for a saline injected (E) and dHACM injected (F) MMT joint. Red = higher attenuation values (lower PG content),
green = lower attenuation values (higher PG content). Black arrows indicate focal defects. The μ-dHACM treated joints did not display lesions on
the tibial articular cartilage surface. EPIC-μCT, equilibrium partitioning of an ionic contrast agent-micro computed tomography; MMT, medial
meniscal transection; PG, proteoglycans; μ-dHACM, micronized dehydrated human amnion/chorion membrane.
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counting each lesion and erosion would be extremely chal-
lenging, and lesion volume would be incalculable given
standard two-dimensional metrics. Additionally, traditional
histological staining only enables assessment of the cartil-
age based on a subjective and semi-quantitative scoring
system, as previously used to screen DMOADs [9,11]. We
also performed histology in this study to compare to ourFigure 5 Quantitative EPIC-μCT data depicting the therapeutic effect
cartilage attenuation was significantly decreased in μ-dHACM treated MMT
tibial plateau. B) Average number of erosions was significantly decreased in
No lesions were observed in the μ-dHACM treated MMT joints. C) Average
EPIC-μCT, equilibrium partitioning of an ionic contrast agent-micro comput
micronized dehydrated human amnion/chorion membrane.EPIC-μCT results by embedding and processing samples
in the sagittal plane. This led to a limitation that the sec-
tions could not be graded by traditional methods as those
require sectioning in the coronal plane. One study tested
MMP inhibitors in the MMT model using outcome mea-
sures based on both semi-quantitative scoring and two-
dimensional measurements for width and depth of cartilage
damage. Due to the inherent variability in these outcomeof μ-dHACM in MMT joints compared to controls. A) Average
joints compared to saline injected MMT joints for the medial one-third
μ-dHACM treated MMT joints compared to saline injected MMT joints.
focal lesion volume in saline injected MMT joints.* p <0.05 and n =5.
ed tomography; MMT, medial meniscal transection; μ-dHACM,
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ficacy of this therapy (20 animals per group) [33]. In con-
trast, in this study we present the EPIC-μCT technique
which allowed objective quantification of three-dimensional
measures with five animals per group, suggesting that these
three-dimensional analyses can provide greater sensitivity
for detection of therapeutic effects. EPIC-μCT thus pro-
vides a higher throughput method with improved predict-
ive capacity to test the effects of DMOADs in pre-clinical
models. Moreover, this is the first study to demonstrate
the protective effect of a single intra-articular injection of
μ-dHACM in the rat MMT OA model.
There are several possible mechanisms by which dHACM
may modulate the progression of OA. A recent study used
ELISA assays to analyze growth factor levels present in μ-
dHACM and showed quantifiable levels of PDGF-AA,
PDGF-BB, TGFα, TGFβ, basic fibroblast growth factor
(bFGF), epidermal growth factor (eGF), placental frowth
factor (PLGF), granulocyte colony stimulating growth fac-
tor, IL-4, IL-6,IL-8, IL-10 and TIMP 1, 2 and 4. The PUR-
ION process allowed μ-dHACM to retain its biological
activity which may play a role in its effect on attenuation
of OA in the rat MMT model. dHACM has been shown
to suppress the expression of potent pro-inflammatory cy-
tokines, such as IL-1α and IL-1β, and also to decrease
MMP levels through expression of natural MMP inhibi-
tors present in the membrane [34,35]. dHACM also
contains IL-1Ra, a receptor antagonist for IL-1, a pro-
inflammatory cytokine that has been shown to be up-
regulated in OA [17]. Two low molecular mass elastase
inhibitors – secretory leukocyte proteinase inhibitor
(SLPI) and elafin – are expressed in the dHACM, both
of which exhibit anti-inflammatory properties [14]. Hya-
luronic acid is also present and acts as a ligand for the
CD44 receptor which is expressed on inflammatory cells
and plays a role in adhesion capabilities of immune cells
[14]. In addition to anti-inflammatory molecules, devi-
talized μ-dHACM particles have been shown to retain a
variety of bioactive substances including multiple
growth factors such as PDGF and FGF [27]. PDGF and
FGF-18 have previously been implicated in chondrocyte
growth [36]. All of these potential mechanisms, includ-
ing maintenance of cartilage homeostasis and reduction
of inflammation and MMP expression, may be active
contributing factors to the observed protective effect of
μ-dHACM. dHACM also retains natural structural com-
ponents, such as collagens (types I, III, IV, V, VI), fibrino-
gen, laminin, nidogen and PGs. While these components
clearly are important for the regulation and maintenance
of normal chondrocyte metabolism, whether the ECM
composition of dHACM directly affects OA is unclear
[26]. However, retention of the active regulatory compo-
nents may be influenced by the size and composition of
the dHACM particles.While the mode of action of a disease modifying ther-
apy is a key component of its efficacy, local retention of
the factor is also thought to be critical. Retention is par-
ticularly challenging when considering small molecule
DMOADs. The particle size of the drug or carrier is crit-
ical since particles less than 6 microns are quickly fil-
tered through intercellular gaps or phagocytosed by
macrophages [37]. Clinical studies measuring residence
time of various NSAIDs delivered intra-articularly found
the half-life to range from 1.1 to 5.2 hours [38]. Alterna-
tively, larger particles likely elicit an immune response
or may cause physical damage to the articular surface
[5]. In this study, the μ-dHACM particles sequestered in
the synovial membrane at three days were large enough
to prevent rapid clearance. Recent research has focused
on extending the residence time of drugs in the joint
cavity via the use of biomaterials including poly-lactic
glycolic acid (PLGA), albumin and bio-polymer based
carriers. In pre-clinical models, drug release from PLGA
particles has been reported to last up to 14 days, but
once released, the drugs were rapidly cleared [39]. Al-
though further studies are needed to elucidate release
kinetics and assess whether extended residence time
translates to increased duration of therapeutic activity,
μ-dHACM presents a potential advantage over other
intra-articular therapeutics due to its retention through
21 days in the synovium, although release kinetics of any
active factors would also play a role. dHACM thus has the
potential to require less-frequent injections to treat OA.
μ-dHACM had not previously been injected into the
joint space; therefore, biocompatibility and inflammatory
responses were evaluated. Histological analysis indicated
moderate local hypercellularity at three days which per-
sisted at twenty-one days. This response was localized to
regions surrounding the μ-dHACM particles and was not
present throughout the synovial membrane. This agreed
with synovial fluid analyses, which demonstrated an in-
crease in MCP-1 for animals treated with μ-dHACM at
three days which was then reduced by twenty-one days.
This increase in MCP-1 in response to μ-dHACM was
not observed in the MMT/saline animals. This could be
due to the fact that the MMT surgery itself caused in-
flammation and masked the upregulation of MCP-1
caused by μ-dHACM treatment. While MCP-1 can acti-
vate and recruit monocytes during inflammation, this
pro-inflammatory state may even support a healing re-
sponse depending on the types of monocytes/macrophages
recruited [40,41]. We did not observe an upregulation in
other pro-inflammatory cytokines. The initial analysis of
the inflammatory response has some limitations as levels
of most cytokines were below the limit of detection by the
ELISA multiplex array. This is likely a technical limitation
due to the challenge of harvesting rat synovial fluid, sensi-
tivity of the synovial fluid assay and the limited volume of
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plore in the future for synovial fluid analysis include using
filter paper absorbent to extract synovial fluid from the
joint space and using a more sensitive ELISA such as mag-
netic bead-based multiplex assays. Another reason for
these aberrations could be due to fact that μ-dHACM is a
xenograft that is being injected in the rat joint. Although
we observed a mild to moderate mononuclear inflamma-
tion, we did not identify granulocytes, which would indi-
cate a chronic inflammatory response. Further work is
needed to characterize fully the cellular components of
the synovial fluid, presence of anti-inflammatory factors as
these were observed in in vitro studies performed by Koob
et al. and determine the pathways by which the inflamma-
tory responses progress.
This is a preliminary study testing the effects of dHACM
in a rat OA model. There are several areas that need future
investigation including greater characterization of the
dHACM material. The role of cytokines and growth fac-
tors needs to be elucidated in further detail as well. Add-
itional areas of investigation include the effects of particle
size, composition of dHACM, timing of injection (pre-
existing OA) and duration of particle residence.
Conclusions
This is the first study demonstrating reduction in cartilage
degeneration in a small animal OA model via a single
intra-articular injection of a devitalized allograft derived
from amniotic membrane. EPIC-μCT, used as an analyt-
ical tool, showed, by way of several quantitative metrics, a
cartilage-protective role for μ-dHACM. Based on the abil-
ity of μ-dHACM to incorporate into the synovial tissue
and maintain residency for at least 21 days, this could be-
come a low frequency injection therapeutic. dHACM is a
minimally manipulated and marketed allograft material
which has been shown to be clinically effective in a variety
of applications and now, through this study, μ-dHACM is
presented as a candidate to further investigate as a poten-
tial disease modifying OA therapy [42,43].Additional files
Additional file 1: Figure S1. Gait analysis data. A) Duty cycle. B) Print
area. Baseline = naïve rats prior to surgery. No differences in duty cycle or
print area were observed in MMT rats compared to baseline. n = 8.
Additional file 2: Table S1. Cytokine ELISA data with standard
deviation - indicates cytokine content lower than limit of detection.
Additional file 3: Figure S2. A-C) 4X Mosaic representative histology
images (H & E) of μ-dHACM treated MMT joints. No lesions are observed
on the surface. D-F) Zoomed in 10X images show cartilage surface. Only
one sample showed surface erosions. G-I) 4X Mosaic representative
histology images (H & E) of saline treated MMT joints. Lesion on sample
is indicated by green arrow (I). J-L) Zoomed in 10X images show cartilage
surface. Saline treated samples display qualitatively greater surface degeneration.
(Black boxes indicated 10X zoomed in areas).Abbreviations
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